Similarly, another more recent case report has confirmed this evidence describing the efficacy of CAB associated with the SRL octreotide in one ACTH-secreting lung carcinoid successfully and rapidly managed before surgery with a 2-week combined treatment of CAB at dosage of 1.5 mg/week associated with 0.05 mg/8 h of octreotide, leading to fast clinical improvement of blood pressure and glucose metabolism [38]. This evidence concerns the gene POMC and lung carcinoid tumor.